Targeting AXL in mesothelioma: From functional characterization to clinical implication

Bhadresha, Kinjal; Mirza, Sheefa; Penny, Clement; Mughal, Muhammed Jameel

doi:10.1016/j.critrevonc.2023.104043

Cited by 2 publications

(1 citation statement)

References 129 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AXL mediates immune escape by restricting pro-inflammatory cytokine expression through the upregulation of BCL-2 and Twist and suppressing inflammatory Toll-like receptor signaling and natural killer cell activity [57,58]. AXL overexpression is found in 75% of MPMs and is associated with poor survival outcomes [43,59].…”

Section: Axlmentioning

confidence: 99%

Emerging New Targets in Systemic Therapy for Malignant Pleural Mesothelioma

Yun,

Bazhenova

2024

Cancers

View full text Add to dashboard Cite

Malignant pleural mesothelioma (MPM) is a heterogeneous cancer composed of distinct molecular and pathologic subtypes. Unfortunately, MPM is aggressive, and current therapies for advanced, unresectable disease remain limited to cytotoxic chemotherapy and immunotherapy. Our understanding of the genomic landscape of MPM is steadily growing, while the discovery of effective targeted therapies in MPM has advanced more slowly than in other solid tumors. Given the prevalence of alterations in tumor suppressor genes in MPM, it has been challenging to identify actionable targets. However, efforts to characterize the genetic signatures in MPM over the last decade have led to a range of novel targeted therapeutics entering early-phase clinical trials. In this review, we discuss the advancements made thus far in targeted systemic therapies in MPM and the future direction of targeted strategies in patients with advanced MPM.

show abstract